脱敏(药物)
内化
快速反应
生物
G蛋白偶联受体
兴奋剂
受体
支气管收缩
信号转导
细胞生物学
S-亚硝基化
哮喘
免疫学
药理学
生物化学
半胱氨酸
酶
作者
Fabio V. Fonseca,Thomas M. Raffay,Kunhong Xiao,Precious J. McLaughlin,Zhaoxia Qian,Zachary W. Grimmett,Naoko Adachi,Benlian Wang,Alfred Hausladen,Brian A. Cobb,Rongli Zhang,Douglas T. Hess,Benjamin Gaston,Nevin A. Lambert,James D. Reynolds,Richard T. Premont,Jonathan S. Stamler
出处
期刊:Molecular Cell
[Elsevier]
日期:2022-08-01
卷期号:82 (16): 3089-3102.e7
被引量:1
标识
DOI:10.1016/j.molcel.2022.06.033
摘要
The β2-adrenergic receptor (β2AR), a prototypic G-protein-coupled receptor (GPCR), is a powerful driver of bronchorelaxation, but the effectiveness of β-agonist drugs in asthma is limited by desensitization and tachyphylaxis. We find that during activation, the β2AR is modified by S-nitrosylation, which is essential for both classic desensitization by PKA as well as desensitization of NO-based signaling that mediates bronchorelaxation. Strikingly, S-nitrosylation alone can drive β2AR internalization in the absence of traditional agonist. Mutant β2AR refractory to S-nitrosylation (Cys265Ser) exhibits reduced desensitization and internalization, thereby amplifying NO-based signaling, and mice with Cys265Ser mutation are resistant to bronchoconstriction, inflammation, and the development of asthma. S-nitrosylation is thus a central mechanism in β2AR signaling that may be operative widely among GPCRs and targeted for therapeutic gain.
科研通智能强力驱动
Strongly Powered by AbleSci AI